Skip to main content
. Author manuscript; available in PMC: 2016 Aug 17.
Published in final edited form as: Ann Thorac Surg. 2016 Jan 20;101(6):2407–2416. doi: 10.1016/j.athoracsur.2015.12.004

Fig 1.

Fig 1

Genetic molecular targets in ischemic heart disease. (c-Myc = proto-oncogene protein; DEL-1 = developmental endothelial locus 1; eNOS = endothelial nitric oxide synthase; E2F = transcription factor; FGF = fibroblast growth factor; HGF = hepatocyte growth factor; HIF-1α = hypoxia inducible factor 1α; MAPK = mitogen-activated protein kinase; MMP = matrix metalloproteinases; NFAT = nuclear factor of activated T cells; NO = nitric oxide; Oral 1/3 = ORAI calcium release-activated calcium modulator 1/3; SERCA2a = sarcoplasmic reticulum adenosine triphosphatase isoform 2a; SMC = smooth muscle cells; STIM-1 = stromal interaction molecule-1; TIMP = tissue inhibitor metalloproteinases; VEGF = vascular endothelial growth factor.)